Sort   by:  
 Page size 

Purpose

To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer.

Patients and methods

The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a phase II, randomized, open-label, multicent...
Sort   by:  
 Page size